Malignant Pericardial Effusion: Causes & Treatment

Malignant pericardial effusion occurs when cancer causes fluid to build up in the sac surrounding the heart, and it is most often traced to lung cancer, breast cancer, lymphoma, or melanoma spreading to the pericardium. Treatment ranges from urgent needle drainage to surgical procedures and locally instilled drugs, depending on how quickly symptoms develop and how long the patient is expected to survive. The condition sits at a difficult intersection of cardiology, oncology, and palliative care, and the choices made in managing it can meaningfully affect both comfort and the time a patient has left.

Which Cancers Cause It and How They Get There

The pericardium can become involved in cancer through three main routes: the tumor grows directly into the pericardial sac from a neighboring structure, cancer cells travel through lymphatic channels, or they arrive via the bloodstream. Lung cancer is the most common culprit simply because of proximity; a tumor in the lung or mediastinum can invade the pericardium without traveling far at all. Breast cancer, melanoma, and lymphoma are the other frequent sources.¹ A large Danish population study also found elevated rates of kidney cancer, bladder cancer, and leukemia among patients who had been diagnosed with pericarditis, suggesting that pericardial inflammation can sometimes be the first visible sign of an undetected malignancy.²

Rarely, the pericardium itself is the origin. Primary malignant pericardial mesothelioma is an extremely uncommon tumor that arises from the lining of the heart sac. A case report described a 37-year-old woman whose pericardial effusion was initially assumed to be viral, then treated empirically for tuberculosis, before a pericardial biopsy finally revealed mesothelioma. She died a year after diagnosis despite chemotherapy.³ The case illustrates how elusive the diagnosis can be when the cancer is not already known.

Cancer treatment itself can also be the cause. Radiation therapy to the chest, commonly used for breast cancer, lymphoma, and lung cancer, can injure the pericardium. Radiation-related pericardial disease sometimes appears during or shortly after treatment, but it can also show up years or even decades later.⁴ This delayed onset means that a patient who finished radiation therapy long ago and has been considered in remission might still develop a pericardial effusion related to their earlier treatment rather than to recurrent cancer, which complicates the diagnostic picture.

Why Speed of Fluid Accumulation Matters More Than Volume

The pericardium is not very stretchy under normal conditions. When fluid appears suddenly, even a relatively small amount can drive pressure dangerously high. An increase of as little as 100 to 200 milliliters, arriving quickly, can push pericardial pressure to levels that define severe cardiac tamponade, a state in which the heart cannot fill properly and blood pressure drops.⁵ This is the scenario that sends patients to the emergency department with distended neck veins, muffled heart sounds, and falling blood pressure.

At the other end of the spectrum, a slow leak over weeks or months gives the pericardium time to stretch and adapt. The pressure-volume curve shifts to the right: the sac accommodates far more fluid before pressure climbs steeply. That is why some patients walk around with liters of pericardial fluid and relatively modest symptoms, while others are in crisis with a fraction of that volume.⁵ For malignant effusions, both patterns exist: a tumor eroding into a blood vessel can produce rapid hemorrhagic accumulation, whereas lymphatic obstruction from a growing mass tends to cause a gradual buildup.

Figuring Out Whether the Effusion Is Malignant

Not every pericardial effusion in a cancer patient is malignant. Infections, autoimmune conditions, hypothyroidism, kidney failure, and side effects of cancer treatment can all produce fluid around the heart. The distinction matters because the treatment strategy changes depending on the cause.

Echocardiography is typically the first imaging step. It confirms the presence of fluid, estimates its volume, and assesses whether the heart is being compressed. CT scans add another layer of information. In one study, abnormal pericardial thickening and enlarged mediastinal lymph nodes were both significantly more common in malignant than in benign effusions, with mean pericardial thickness roughly 7 mm in malignant cases versus about 4 mm in benign ones.⁶ MRI with diffusion-weighted sequences has also shown promise as a way to distinguish malignant from benign fluid without invasive sampling, though it remains more of a research tool than a routine clinical test.⁷

When the fluid is actually drained, sending it to the lab for cytology is the most direct way to confirm malignancy. A multi-institutional analysis found that pericardial fluid cytology identified malignant cells in about 85% of truly malignant cases, compared with roughly 66% for tissue biopsy, making cytology the more sensitive of the two.⁸ A separate study echoed this, finding that cytology detected more malignant cases than surgical specimens when ambiguous results were set aside.⁹ The practical takeaway is that if the fluid is being removed anyway, examining it under the microscope is the single most useful diagnostic step.

Biochemical markers in the fluid itself can also help. Malignant effusions tend to have higher levels of tumor markers like CEA and CA 72-4, higher white blood cell counts, and higher LDH levels than benign effusions. Measuring CA 72-4 in particular showed high diagnostic accuracy, especially when the fluid was bloody, a common finding in cancer-related effusions.¹⁰

Emergency Drainage and Extended Catheter Use

When tamponade is present or imminent, the first priority is getting fluid out. Percutaneous pericardiocentesis, inserting a needle through the chest wall and into the pericardial space under imaging guidance, is the standard emergency approach. A study of cancer patients undergoing this procedure found it to be safe and effective as a primary treatment, including in patients with low platelet counts, a common concern in cancer patients receiving chemotherapy.¹¹

The problem with simple drainage is that the fluid often comes back. In patients with non-small-cell lung cancer, simple pericardiocentesis alone had a median recurrence-free survival of less than two months, and only about one in five patients remained free of recurrence at one year.¹² For a patient whose expected survival is weeks rather than months, that recurrence rate may be acceptable. For someone with a longer horizon, it usually is not, and a more durable solution is needed.

Procedures to Prevent Fluid From Coming Back

Several approaches aim to create a lasting pathway for fluid to drain or to make the pericardial surfaces stick together so fluid cannot re-accumulate.

Balloon Pericardiotomy

Percutaneous balloon pericardiotomy involves threading a balloon catheter into the pericardial space and inflating it to create a tear in the pericardium, allowing fluid to drain continuously into the surrounding pleural space, where the body can absorb it more easily. It is performed through a needle puncture rather than open surgery. One study described it as a simple, safe technique that can prevent recurrence in many patients with severe malignant pericardial effusion, and one that is particularly useful for avoiding more aggressive surgical approaches that these patients may tolerate poorly.¹³ In the lung cancer study mentioned above, balloon pericardiotomy roughly tripled the median recurrence-free interval compared with simple drainage.¹²

Surgical Pericardial Window

A pericardial window is a small opening cut in the pericardium, usually accompanied by removal of a section of tissue. It can be done through a subxiphoid incision (a small cut below the breastbone) or using video-assisted thoracoscopic surgery (VATS), which uses small ports between the ribs and a camera. Both approaches work, and their recurrence rates are roughly similar in some studies.¹⁴ However, a comparative study found that while VATS required more operating time and caused more minor procedural complications, it was an independent predictor of freedom from effusion recurrence over the long term, with recurrence after the thoracoscopic approach taking roughly three times as long to develop as after the subxiphoid approach.¹⁵ A separate study in a different patient population similarly found VATS to be an independent predictor of remaining free from recurrence.¹⁶

The choice between subxiphoid and VATS approaches often comes down to the patient’s overall condition. The subxiphoid route can be done under local anesthesia with sedation, which makes it more feasible for very sick patients who cannot tolerate general anesthesia. VATS requires general anesthesia and single-lung ventilation but gives the surgeon a better view and the ability to biopsy suspicious tissue. There is also a practical advantage: VATS creates a window that opens into the pleural space, which has a large surface area for absorbing the fluid that drains through.

Sclerosing Agents Instilled Into the Pericardium

After the fluid is drained, a drug can be injected directly into the pericardial space to cause inflammation that seals the two layers of the pericardium together, preventing fluid from re-accumulating. Bleomycin and cisplatin produce the best recurrence-prevention rates in the literature.¹⁷ A head-to-head trial comparing bleomycin with doxycycline found the two agents equally effective, but bleomycin caused significantly fewer side effects and was recommended as the first-line sclerosing agent.¹⁸

Cisplatin, being a chemotherapy drug, offers a different rationale: it may both sclerose the pericardium and kill residual cancer cells in the space. One study found that pericardiocentesis with catheter drainage plus cisplatin instillation was safe and effective for malignant effusion and tamponade, and that the cisplatin prevented recurrence.¹⁹ A more recent case series reported that four out of six patients treated with intrapericardial bleomycin responded well, with symptom resolution and no recurrence, and no serious systemic toxicity was observed.²⁰ These local instillation approaches do not appear to improve overall survival, but preventing recurrence is considered valuable in its own right because it avoids a complication that can be fatal.¹⁷

Systemic Cancer Treatment and the Pericardial Effusion

When the underlying cancer responds to chemotherapy or immunotherapy, the pericardial effusion sometimes resolves along with it. This is most likely with chemotherapy-sensitive tumors like lymphoma and certain breast cancers. A patient with untreated breast cancer, for instance, might undergo a pericardiocentesis for symptom relief and then start systemic therapy with a reasonable expectation that the effusion will not return.

The role of immune checkpoint inhibitors has been a question mark, partly because pericardial effusion has traditionally been seen as a marker of aggressive, treatment-resistant disease. A global multicenter retrospective study specifically examined this in advanced non-small-cell lung cancer and found that immunotherapy worked about as well in patients who had pericardial effusions as in those who did not. Median overall survival was roughly 10 months in the pericardial effusion group, which was not statistically different from the control group’s roughly 15 months.²¹ The finding is encouraging because it suggests that a pericardial effusion alone should not disqualify a patient from receiving immunotherapy, a treatment that can occasionally produce durable responses.

Prognosis and What Shapes It

Malignant pericardial effusion is a late-stage finding, and survival statistics reflect that reality. In one surgical series, the overall median survival after a pericardial procedure was about two and a half months, with only about one in six patients alive at one year.²² A different series reported a somewhat more favorable median of five months, but that study included patients with hematologic cancers, who did dramatically better than those with solid tumors, reaching a median survival of three years.²³ Lung cancer patients consistently fare worst, with median survival under three months in the surgical series.²²

Several factors help predict which patients will do better or worse. A study that performed multivariate analysis identified poor performance status, development of the effusion while already on chemotherapy (suggesting treatment-resistant disease), enlarged mediastinal lymph nodes, and certain cytologic characteristics as significant negative prognostic factors. The overall one-year survival rate in that cohort was about 28%.²⁴ Another study identified an ominous complication called paradoxical hemodynamic instability, a drop in blood pressure that occurs after pericardiocentesis rather than the expected improvement. Patients who developed this had a median survival of only 35 days, compared with about six months in those who did not, and more than half of them did not survive their hospitalization.²³

Choosing a Treatment Strategy

The wide range of options for malignant pericardial effusion exists because no single approach is right for everyone. The decision depends on how urgently the effusion threatens the patient’s life, what kind of cancer is involved, how the cancer is responding (or expected to respond) to systemic treatment, and how much time the patient is likely to have.

For someone with tamponade or near-tamponade, percutaneous pericardiocentesis is the immediate step regardless of anything else. The question is what comes next. A patient with a very short expected survival, perhaps measured in weeks, may not benefit from a surgical window or sclerosing agent. Simple drainage may be enough if the fluid is unlikely to re-accumulate before the end of life. At the other end, a patient with a hematologic malignancy and a potentially responsive tumor might undergo a pericardial window followed by aggressive systemic therapy and have years ahead. Existing literature suggests that surgical drainage tends to be better than non-surgical approaches for symptom relief and recurrence prevention, but the absence of randomized controlled trials makes selection bias a serious limitation.²⁵

A multidisciplinary approach is strongly recommended, ideally pulling together input from cardiology, medical oncology, radiation oncology, and thoracic surgery. And importantly, comfort-focused care without any specific intervention for the effusion itself is a legitimate option for patients with very short expected survival or for those who prefer not to undergo invasive procedures. Although the condition is usually incurable, a reasonable period of useful palliation can be achieved in most patients.²⁶

When the Effusion Appears Before the Cancer Diagnosis

Sometimes a pericardial effusion is the first thing that leads to the discovery of cancer. A patient shows up with shortness of breath, an echocardiogram reveals a large effusion, and the fluid turns out to be malignant. The Danish population study found that patients with a new diagnosis of pericarditis had a roughly 50% higher rate of cancer diagnosis than expected in the general population, with the excess driven by lung, kidney, and bladder cancers as well as lymphoma and leukemia.² This does not mean that every case of pericarditis warrants a cancer workup, since viral and idiopathic pericarditis remain far more common. But a large, unexplained, or bloody pericardial effusion in someone without an obvious benign cause should raise the question, especially in older patients or those with risk factors for malignancy.

The mesothelioma case described earlier is an extreme example of how long this diagnostic process can take. The patient went through an emergency pericardiocentesis, was treated for presumed viral pericarditis, then given empirical tuberculosis therapy, before the true diagnosis finally emerged through a surgical biopsy.³ Clinicians aware of primary pericardial malignancies tend to pursue tissue diagnosis earlier when the effusion keeps coming back without an explanation, but rare tumors like these remain easy to miss.

Ethical Tensions in Late-Stage Management

Malignant pericardial effusion sits squarely in the territory where the capacity to intervene and the wisdom of doing so can diverge. A pericardiocentesis can relieve tamponade in minutes and feel like a lifesaving act, but if the patient’s cancer is refractory to all available treatment and their expected survival is days, the relief may be temporary and the procedure itself carries discomfort, risk, and the possibility of hospitalization that a patient might prefer to avoid. The broader ethical framework around futility in cancer care emphasizes that aggressive intervention should be reserved for patients likely to benefit, while excellent supportive care is the greatest service that can be offered to those who are not.²⁷

In practice, these conversations are rarely clean. Families want everything done, or patients are too sick to participate meaningfully in decisions, or the prognosis is genuinely uncertain. This is one of the areas in oncology where an honest conversation about expected survival, the probability of recurrence, and the goals of care can do more good than any catheter or sclerosing agent. The fact that so many treatment options exist can paradoxically make things harder, because the existence of another procedure can make it feel like giving up to choose not to pursue one.

1
PubMed Central. Pericardial effusion in oncological patients: current knowledge and principles of management
2
PubMed Central. Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality
3
PubMed Central. Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause
4
PubMed. Radiation-Induced Pericardial Disease: Mechanisms, Diagnosis, and Treatment
5
BMJ Journals. Pericardial effusion: haemodynamic spectrum
6
PubMed. CT findings in patients with pericardial effusion: differentiation of malignant and benign disease
7
PubMed. Differentiation malignant from benign pericardial effusion with diffusion-weighted MRI
8
Cytopathology. Higher sensitivity of pericardial fluid cytology than biopsy in malignant effusions with potential explanation of false-negative cytology: A multi-institutional analysis
9
PubMed. Pericardial fluid evaluation: Diagnostic yield and cytology-histology correlation
10
PubMed. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion
11
PubMed Central. Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion
12
PubMed Central. Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer
13
PubMed. Percutaneous balloon pericardiotomy as the initial and definitive treatment for malignant pericardial effusion
14
Dicle Medical Journal. The efficacy of VATS, subxiphoid and minithoracotomy pericardial window for surgical management of symptomatic pericardial effusions
15
PubMed. Comparative study of subxiphoid versus video-thoracoscopic pericardial “window”
16
Journal of the Egyptian Society of Cardio-Thoracic Surgery. Thoracoscopic versus subxiphoid pericardial window in patients with end-stage renal disease
17
PubMed. Intrapericardial instillation of bleomycin prevents recurrence of malignant pericardial effusions: Series of 46 cases and comprehensive literature review
18
PubMed. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade
19
PubMed Central. Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade
20
International Journal of Medical and Pharmaceutical Research. A Foe For Lung Is A Friend For Heart: Intrapericardial Bleomycin For Malignant Pericardial Effusion – A Case Series
21
PubMed Central. Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study
22
PubMed Central. Survival post surgery for malignant pericardial effusion
23
PubMed. Pericardial effusions in the cancer population: prognostic factors after pericardial window and the impact of paradoxical hemodynamic instability
24
PubMed. Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients
25
PubMed. Palliative treatment for symptomatic malignant pericardial effusion
26
PubMed Central. Managing malignant pericardial effusion.
27
PubMed. Medical futility and appropriate medical care in patients whose death is thought to be imminent